Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from AbCellera Biologics

I Asked ChatGPT’s Most Advanced Model to Find the Stocks Most Likely to 100x Over the Next 10 Years — Here’s What It Said

Here are the stocks that ChatGPT's most advanced model says are most likely to 100x over the next 10 years.

Peter Thiel Made A Fortune On Palantir — Here Are His 3 Other Bets

Peter Thiel Made A Fortune On Palantir — Here Are His 3 Other Bets

Peter Thiel is a master at putting his money in the right place at the right time. New S&P 500 member Palantir is just one big bet.

Investors Business Daily

Should You Follow Insider Buying on This Biotech Penny Stock?

Should You Follow Insider Buying on This Biotech Penny Stock?

With significant insider purchases and high-profile hedge fund interest, AbCellera is one penny stock to watch.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

1 Billionaire-Backed Penny Stock With 421% Upside

Down 96% from all-time highs, AbCellera Biologics is a biotech stock with massive upside potential, given consensus price target estimates.

3 AI-Driven Drug Stocks to Buy Before They Breakout

The pharma sector is expected to undergo a huge disruption, thanks to the impact of artificial intelligence. Here are three companies that Wall Street analysts think could benefit, based on their AI-driven R&D.

AbCellera Biologics Clears Key Benchmark, Hitting 80-Plus RS Rating

A Relative Strength Rating upgrade for AbCellera Biologics shows improving technical performance.

Investors Business Daily

IBD Stock Of The Day AbCellera Is Pulling Back — Why Investors Should Be Paying Attention

Antibody machine AbCellera Biologics is the IBD Stock Of The Day as ABCL stock eyes a potential entry following a brief pullback.

Investors Business Daily

inkl

Read news from The Economist, FT, and more,
with one subscription

Abcellera Biologics Clears Technical Benchmark, Hitting 90-Plus RS Rating

Abcellera Biologics Clears Technical Benchmark, Hitting 90-Plus RS Rating

A Relative Strength Rating upgrade for Abcellera Biologics Inc shows improving technical performance.

Investors Business Daily

AbCellera Biologics's Return On Capital Employed Insights

AbCellera Biologics's Return On Capital Employed Insights

According to Benzinga Pro, during Q1, AbCellera Biologics (NASDAQ:ABCL) earned $168.57 million, a 181.2% increase from the preceding quarter. AbCellera Biologics also posted a total of $316.58 million in sales, a 127.22% increase since Q4.

What 4 Analyst Ratings Have To Say About AbCellera Biologics

What 4 Analyst Ratings Have To Say About AbCellera Biologics

Over the past 3 months, 4 analysts have published their opinion on AbCellera Biologics (NASDAQ:ABCL) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Recap: AbCellera Biologics Q1 Earnings

Recap: AbCellera Biologics Q1 Earnings

AbCellera Biologics (NASDAQ:ABCL) reported its Q1 earnings results on Tuesday, May 10, 2022 at 04:00 PM. Here's what investors need to know about the announcement.

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

SP Global Market Intelligence

Aehr Test Systems

Ginkgo Bioworks

AbCellera Biologics

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Artificial Intelligence

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play